Salarius Pharmaceuticals (SLRX) Revenue & Revenue Breakdown

Salarius Pharmaceuticals Revenue Highlights

Main Segment (Y)

Grant, Castration-Resistant Prostate Study

Main Geography (Y)

Grant, Castration-Resistant Prostate Study

Salarius Pharmaceuticals Revenue by Period

Salarius Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	-	100.00%
2022-12-31	-	-100.00%
2021-12-31	$1.84M	-64.84%
2020-12-31	$5.23M	51.03%
2019-12-31	$3.47M	313.49%
2018-12-31	$838.00K	-34.27%
2017-12-31	$1.27M	26.11%
2016-12-31	$1.01M	100.00%
2015-12-31	-	-

Salarius Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Salarius Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	-	100.00%
2024-06-30	-	100.00%
2024-03-31	-	-100.00%
2023-12-31	$17.89K	100.00%
2023-09-30	-	100.00%
2023-06-30	-	100.00%
2023-03-31	-	100.00%
2022-12-31	-	100.00%
2022-09-30	-	100.00%
2022-06-30	-	100.00%
2022-03-31	-	-100.00%
2021-12-31	$-1.84M	100.00%
2021-09-30	-	-100.00%
2021-06-30	$571.39K	-54.97%
2021-03-31	$1.27M	-14.21%
2020-12-31	$1.48M	7.31%
2020-09-30	$1.38M	10.85%
2020-06-30	$1.24M	9.75%
2020-03-31	$1.13M	9.06%
2019-12-31	$1.04M	18.71%
2019-09-30	$874.95K	431.22%
2019-06-30	$164.71K	56.90%
2019-03-31	$104.98K	-35.60%
2018-12-31	$163.00K	-35.06%
2018-09-30	$250.99K	2.24%
2018-06-30	$245.50K	37.47%
2018-03-31	$178.58K	-36.90%
2017-12-31	$283.00K	-31.58%
2017-09-30	$413.60K	23.27%
2017-06-30	$335.52K	38.33%
2017-03-31	$242.55K	-18.88%
2016-12-31	$299.00K	-50.09%
2016-09-30	$599.07K	431.64%
2016-06-30	$112.69K	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	-

Salarius Pharmaceuticals generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Salarius Pharmaceuticals Revenue Breakdown

Salarius Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 20	Dec 18
Grant, Castration-Resistant Prostate Study	$2.60M	-
Product and Service, Other	-	$11.63K
Product	-	$826.51K

Salarius Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 20: Grant, Castration-Resistant Prostate Study (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Mar 21	Sep 20	Jun 20	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
Grant	$100.00K	$100.00K	-	-	-	-	-	-	-	-	-
Grant, Castration-Resistant Prostate Study	-	-	$2.60M	$2.60M	$2.60M	-	-	-	-	-	-
Product	-	-	-	-	-	$163.07K	$104.22K	$161.56K	$247.28K	$241.42K	-
Product and Service, Other	-	-	-	-	-	$1.63K	$757.00	$1.51K	$3.71K	$4.09K	-
Consumer Operations	-	-	-	-	-	-	-	-	-	-	$178.58K
Drug Development	-	-	-	-	-	-	-	-	-	-	-

Salarius Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Grant (100.00%).

Salarius Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 20	Dec 18
Grant, Castration-Resistant Prostate Study	$2.60M	-
Product and Service, Other	-	$11.63K
Product	-	$826.51K

Salarius Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: Grant, Castration-Resistant Prostate Study (100.00%).

Quarterly Revenue by Country

Country	Mar 21	Sep 20	Jun 20	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
Grant, Castration-Resistant Prostate Study	$2.60M	$2.60M	$2.60M	-	-	-	-	-	-
Product and Service, Other	-	-	-	$1.63K	$757.00	$1.51K	$3.71K	$4.09K	-
Product	-	-	-	$163.07K	$104.22K	$161.56K	$247.28K	$241.42K	-
Drug Development	-	-	-	-	-	-	-	-	-
Consumer Operations	-	-	-	-	-	-	-	-	$178.58K

Salarius Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 21: Grant, Castration-Resistant Prostate Study (100.00%).

Salarius Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PIRS	Pieris Pharmaceuticals	$42.81M	-
MREO	Mereo BioPharma Group	$10.00M	-
AFMD	Affimed	$8.28M	$155.00K
SABS	SAB Biotherapeutics	$2.24M	$263.14K
NTRB	Nutriband	$2.09M	$645.80K
VCNX	Vaccinex	$570.00K	$52.00K
CRVS	Corvus Pharmaceuticals	-	-
ALRN	Aileron Therapeutics	-	-
AKTX	Akari Therapeutics	-	-
GOVX	GeoVax Labs	-	$300.68K
ARTL	Artelo Biosciences	-	-
SLRX	Salarius Pharmaceuticals	-	-

SLRX Revenue FAQ

What is Salarius Pharmaceuticals’s yearly revenue?

Salarius Pharmaceuticals's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. SLRX's yearly revenue for 2021 was $1.84M, representing a decrease of -64.84% compared to 2020.

What is Salarius Pharmaceuticals’s quarterly revenue?

Salarius Pharmaceuticals's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). SLRX's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Salarius Pharmaceuticals’s revenue growth rate?

Salarius Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.

What are Salarius Pharmaceuticals’s revenue streams?

Salarius Pharmaceuticals's revenue streams in c 20 are Grant, Castration-Resistant Prostate Study

What is Salarius Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 20, the largest source of revenue of Salarius Pharmaceuticals was Grant, Castration-Resistant Prostate Study. This segment made a revenue of $2.6M, representing 100.00% of the company's total revenue.